AB0943 Sustained improvements with up to 104 weeks of apremilast monotherapy in biologic-naÏve subjects with active psoriatic arthritis: results from a phase 3b, randomised, controlled trial
Peter Nash(Griffith University), Jacob Aelion(Middle Tennessee Research Institute), Jessica A. Walsh(VA Salt Lake City Healthcare System), Nikolay Delev(Bristol-Myers Squibb (Sweden)), Kamal Ohson(Memorial University of Newfoundland), Juan J. Gómez‐Reino(Hospital Clínico Universitario de Valencia), D. Nguyen, Maria Paris(Amgen (United States)), Lichen Teng(Harbin Medical University)
Cited by 0
Related Papers
Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase <scp>II</scp>, Randomized, <scp>Double‐Blind</scp>, <scp>Placebo‐Controlled</scp> Trial
|Arthritis & Rheumatology|2022|261
New Sequence Variants in HLA Class II/III Region Associated with Susceptibility to Knee Osteoarthritis Identified by Genome-Wide Association Study
|PLoS ONE|2010|125
A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis
|Arthritis Research & Therapy|2015|116
N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study
|Arthritis Research & Therapy|2012|114
Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
|Annals of the Rheumatic Diseases|2018|88